152 related articles for article (PubMed ID: 29930489)
1. Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer.
Kim DJ; Kim WJ; Lim M; Hong Y; Lee SJ; Hong SH; Heo J; Lee HY; Han SS
J Korean Med Sci; 2018 Jun; 33(26):e178. PubMed ID: 29930489
[TBL] [Abstract][Full Text] [Related]
2. Correlation between Plasma Cellular Retinoic Acid-Binding Protein 2 and Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer Cells.
Meng JF; Luo MJ; Li HB
Crit Rev Eukaryot Gene Expr; 2021; 31(3):81-89. PubMed ID: 34369716
[TBL] [Abstract][Full Text] [Related]
3. RNA sequencing identifies novel markers of non-small cell lung cancer.
Han SS; Kim WJ; Hong Y; Hong SH; Lee SJ; Ryu DR; Lee W; Cho YH; Lee S; Ryu YJ; Won JY; Rhee H; Park JH; Jang SJ; Lee JS; Choi CM; Lee JC; Lee SD; Oh YM
Lung Cancer; 2014 Jun; 84(3):229-35. PubMed ID: 24751108
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer.
Favorskaya I; Kainov Y; Chemeris G; Komelkov A; Zborovskaya I; Tchevkina E
Tumour Biol; 2014 Oct; 35(10):10295-300. PubMed ID: 25034531
[TBL] [Abstract][Full Text] [Related]
5. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
6. The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis.
Zeng S; Xu Z; Liang Q; Thakur A; Liu Y; Zhou S; Yan Y
Chem Biol Interact; 2023 Mar; 373():110372. PubMed ID: 36736488
[TBL] [Abstract][Full Text] [Related]
7. Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas.
Percicote AP; Mardegan GL; Gugelmim ES; Ioshii SO; Kuczynski AP; Nagashima S; de Noronha L
Diagn Pathol; 2018 Jan; 13(1):9. PubMed ID: 29378601
[TBL] [Abstract][Full Text] [Related]
8. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
Blasberg JD; Pass HI; Goparaju CM; Flores RM; Lee S; Donington JS
J Clin Oncol; 2010 Feb; 28(6):936-41. PubMed ID: 20085934
[TBL] [Abstract][Full Text] [Related]
9. CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status.
Feng X; Zhang M; Wang B; Zhou C; Mu Y; Li J; Liu X; Wang Y; Song Z; Liu P
J Exp Clin Cancer Res; 2019 Aug; 38(1):361. PubMed ID: 31419991
[TBL] [Abstract][Full Text] [Related]
10. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
11. Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin β1/FAK/ERK Signaling.
Wu JI; Lin YP; Tseng CW; Chen HJ; Wang LH
Sci Rep; 2019 Jan; 9(1):845. PubMed ID: 30696915
[TBL] [Abstract][Full Text] [Related]
12. CRABP2 - A novel biomarker for high-risk endometrial cancer.
Egan D; Moran B; Wilkinson M; Pinyol M; Guerra E; Gatius S; Matias-Guiu X; Kolch W; le Roux CW; Brennan DJ
Gynecol Oncol; 2022 Nov; 167(2):314-322. PubMed ID: 36163055
[TBL] [Abstract][Full Text] [Related]
13. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
16. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
17. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
